Bioporto A/S logo

BIOPOR - Bioporto A/S News Story

DKK3.97 0.0  0.0%

Last Trade - 12/05/21

Small Cap
Market Cap £123.0m
Enterprise Value £114.2m
Revenue £2.85m
Position in Universe 846th / 1832

Completion of share capital increase

Tue 20th November, 2018 10:18am
Completion of share capital increase


November 20, 2018

Announcement no. 22


Completion of share capital increase

The Board of Directors of BioPorto A/S (BioPorto) decided on November 11, 2018 to partially exercise the authorization in article 16b of the company’s Articles of Association to issue new shares in a private placement to a limited number of shareholders, institutional and financial investors, cf. company announcement no. 19 of November 11, 2018. As announced in company announcement no. 20 of November 12, 2018, the issue was fully subscribed.

Completion of the issue

BioPorto has now received the full subscription amount and the capital increase of in total nominally DKK 10,178,117 has been registered with the Danish Business Authority.

BioPorto’s gross proceeds from the issue amount to approximately DKK 40.0 million. The aggregate net proceeds are expected to amount to approximately DKK 39.5 million after deduction of costs.

Admission to trading and official listing

The new shares will as soon as possible be admitted to trading and official listing on Nasdaq Copenhagen A/S under the ISIN code of the company’s existing shares (ISIN DK0011048619).

Share capital after the rights issue

As a result of the issue, BioPorto’s share capital has been increased by nominally DKK 10,178,117. Accordingly, the total share capital of BioPorto now amounts to DKK 165,687,798 divided into 165,687,798 shares of nominally DKK 1 each, equivalent to 165,687,798 votes. BioPorto’s Articles of Association have been updated accordingly and are available on the company’s website.

For further information please contact:

Peter Mørch Eriksen, CEO

Ole Larsen, CFO

Tel.: 45 29 00 00, e-mail


© Stockopedia 2021, Refinitiv, Share Data Services.
This site cannot substitute for professional investment advice or independent factual verification. To use it, you must accept our Terms of Use, Privacy and Disclaimer policies.